NASDAQ$DVAX
Dynavax Technologies Corp · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Dynavax's financial performance for Q2 2021 was reported, featuring record HEPLISAV-B revenue and progress in CpG 1018 collaborations.
Dynavax reported a successful Q2 2021, marked by record HEPLISAV-B revenue of $13.7 million and significant CpG 1018 revenue of $39 million driven by multiple commercial supply agreements. The company achieved a net income of $4.5 million, a substantial improvement from the previous year's net loss.
- Total revenue for the second quarter of 2021 was $52.8 million, a significant increase from $2.7 million in the same period of 2020.
- HEPLISAV-B achieved its highest quarterly revenue to date at $13.7 million, driven by increased market share in targeted accounts.
- CpG 1018 adjuvant generated $39.0 million in revenue during the quarter, supported by multiple commercial supply agreements with COVID-19 vaccine collaborators.
- Net income for the second quarter of 2021 was $4.5 million, a significant turnaround from the net loss of $51.6 million in the second quarter of 2020.
Headline financials
Revenue & EPS history
Dynavax · Revenue · Quarterly
$52.8M
Revenue by segment
Dynavax · $13.7M total across 1 segment · Q2 2021
- HEPLISAV-B Net Product Revenue$13.7M+469.6%100.0%
Forward guidance
Dynavax anticipates several milestones, including a CDC vote on universal hepatitis B recommendation, data readouts from CpG 1018 COVID-19 collaboration partners, and data from the Tdap-1018 Phase 1 clinical trial.
Tailwinds
- Potential for emergency or conditional use authorization of COVID-19 vaccines by the end of 2021.
- Expected vote on a universal hepatitis B recommendation for all previously unvaccinated adults in October.
- Data from Tdap-1018 in the ongoing Phase 1 clinical trial expected in the first quarter of 2022.
- Multiple data readouts from CpG 1018 COVID-19 collaboration partners.
- Continued progress in commercializing HEPLISAV-B.
Headwinds
- Risks related to the timing and result of the ACIP vote on a universal hepatitis b recommendation.
- Risks that collaborators will not get approval of their vaccine candidates.
- Risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018.
- Risks related to whether, when and the quantity of CpG 1018 actually purchased by vaccine companies.
- Risks related to the use of contract manufacturers to supply CpG 1018 and financial commitments made to them.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
-0.6%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+0.9%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+18.1%
Q1 2019
Best reaction
-29.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.5% | +2.4% | -1.0% | |
| Q2 2025 | -6.7% | -2.2% | -9.0% | |
| Q1 2025 | -11.0% | -9.6% | -6.1% | |
| Q4 2024 | +0.0% | +2.5% | +3.6% | |
| Q3 2024 | +5.9% | +9.6% | +4.5% | |
| Q2 2024 | +6.8% | +10.1% | +7.2% | |
| Q1 2024 | -6.4% | -6.2% | +2.6% | |
| Q4 2023 | +2.3% | +4.3% | -1.4% | |
| Q3 2023 | +0.9% | -5.5% | -2.8% | |
| Q2 2023 | +7.1% | +10.0% | +7.4% | |
| Q1 2023 | +4.8% | +7.0% | +9.0% | |
| Q4 2022 | -5.0% | -5.5% | -9.4% | |
| Q3 2022 | +11.6% | +10.3% | +12.6% | |
| Q2 2022 | +17.8% | +20.7% | -20.6% | |
| Q1 2022 | -4.3% | -12.0% | +29.7% | |
| Q4 2021 | -2.2% | -16.1% | -11.8% | |
| Q3 2021 | -22.8% | — | — | |
| Q2 2021 | +6.1% | — | — | |
| Q1 2021 | +9.7% | — | — | |
| Q4 2020 | -6.7% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | -13.5% | — | — | |
| Q1 2020 | -8.8% | — | — | |
| Q4 2019 | -29.1% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +5.2% | — | — | |
| Q1 2019 | +18.1% | — | — | |
| Q4 2018 | -7.8% | — | — | |
| Q3 2018 | +2.2% | — | — | |
| Q2 2018 | +5.8% | — | — | |
| Q1 2018 | -5.0% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +6.4% | — | — | |
| Q2 2017 | +12.7% | — | — | |
| Q1 2017 | +0.9% | — | — | |
| Q4 2016 | -2.5% | — | — | |
| Q3 2016 | +6.7% | — | — | |
| Q2 2016 | -2.3% | — | — | |
| Q1 2016 | +8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +10.8% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -9.2% | — | — | |
| Q1 2014 | -3.9% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | +4.5% | — | — | |
| Q2 2013 | +2.4% | — | — | |
| Q1 2013 | -5.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | -3.6% | — | — | |
| Q4 2011 | +3.1% | — | — | |
| Q3 2011 | -14.0% | — | — | |
| Q2 2011 | -14.6% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -8.1% | — | — | |
| Q1 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro